Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH, Brandts C, Serve H, Roesel J, Giles F, Feldman E, Ehninger G, Schiller GJ, Nimer S, Stone RM, Wang Y, Kindler T, Cohen PS, Huber C, Fischer T. Heidel F, et al. Among authors: serve h. Blood. 2006 Jan 1;107(1):293-300. doi: 10.1182/blood-2005-06-2469. Epub 2005 Sep 8. Blood. 2006. PMID: 16150941 Free article.
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Löffler H, Sauerland CM, Serve H, Büchner T, Haferlach T, Hiddemann W. Schnittger S, et al. Among authors: serve h. Blood. 2002 Jul 1;100(1):59-66. doi: 10.1182/blood.v100.1.59. Blood. 2002. PMID: 12070009 Free article.
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.
Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, Flasshove M, Ottmann OG, Jung W, Cavalli F, Kuse R, Thomalla J, Serve H, O'Farrell AM, Jacobs M, Brega NM, Scigalla P, Hossfeld DK, Berdel WE. Fiedler W, et al. Among authors: serve h. Blood. 2003 Oct 15;102(8):2763-7. doi: 10.1182/blood-2002-10-2998. Epub 2003 Jul 3. Blood. 2003. PMID: 12843001 Free article. Clinical Trial.
High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets.
Müller-Tidow C, Schwäble J, Steffen B, Tidow N, Brandt B, Becker K, Schulze-Bahr E, Halfter H, Vogt U, Metzger R, Schneider PM, Büchner T, Brandts C, Berdel WE, Serve H. Müller-Tidow C, et al. Among authors: serve h. Clin Cancer Res. 2004 Feb 15;10(4):1241-9. doi: 10.1158/1078-0432.ccr-0954-03. Clin Cancer Res. 2004. PMID: 14977821
Flt3 receptor tyrosine kinase as a drug target in leukemia.
Schmidt-Arras D, Schwäble J, Böhmer FD, Serve H. Schmidt-Arras D, et al. Among authors: serve h. Curr Pharm Des. 2004;10(16):1867-83. doi: 10.2174/1381612043384394. Curr Pharm Des. 2004. PMID: 15180525 Review.
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E, Ehninger G, Schiller G, Klimek V, Nimer SD, Gratwohl A, Choudhary CR, Mueller-Tidow C, Serve H, Gschaidmeier H, Cohen PS, Huber C, Fischer T. Kindler T, et al. Among authors: serve h. Blood. 2005 Jan 1;105(1):335-40. doi: 10.1182/blood-2004-02-0660. Epub 2004 Sep 2. Blood. 2005. PMID: 15345593 Free article.
372 results